VBI Vaccines (BST:LO9A) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LO9A Overzicht aandelen

A commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.

Over het bedrijf

LO9A fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Risicoanalyse

Aandelen zijn zeer illiquide

Negatief eigen vermogen

Heeft geen betekenisvolle marktkapitalisatie ( €631K )

De winst is de afgelopen 5 jaar met 17.4% per jaar gedaald

+ 1 meer risico

VBI Vaccines Inc. Concurrenten

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Paion

XTRA:PA8

€2.6m

Paion

DB:PA8K

€45.7k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor VBI Vaccines
Historische aandelenkoersen
Huidige aandelenkoers	US$0.03
52 Week Hoogtepunt	US$0.98
52 Week Laag	US$0.01
Bèta	2.17
11 maand verandering	n/a
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-99.96%
5 jaar verandering	n/a
Verandering sinds IPO	-99.97%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	LO9A	DE Biotechs	DE Markt
7D	0%	0.5%	-1.4%
1Y	n/a	-16.2%	11.8%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe LO9A presteerde ten opzichte van de German Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe LO9A presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is LO9A's price volatile compared to industry and market?
LO9A volatility
LO9A Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van LO9A is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van LO9A in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	135	Jeff Baxter	www.vbivaccines.com

VBI Vaccines Inc. Samenvatting

Hoe verhouden de winst en inkomsten van VBI Vaccines zich tot de beurswaarde?
LO9A fundamentele statistieken
Marktkapitalisatie	€567.15k
Inkomsten(TTM)	-€75.49m
Inkomsten(TTM)	€8.46m

0.1x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is LO9A overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LO9A resultatenrekening (TTM)
Inkomsten	US$9.41m
Kosten van inkomsten	US$11.67m
Brutowinst	-US$2.26m
Overige uitgaven	US$81.73m
Inkomsten	-US$83.99m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.93
Brutomarge	-24.03%
Nettowinstmarge	-892.47%
Schuld/Eigen Vermogen Verhouding	-891.6%

Hoe presteerde LO9A op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

LO9A Overzicht aandelen

Beloningen

Risicoanalyse

VBI Vaccines Inc. Concurrenten

HMSE:SBH

€419.8k

BST:BPXA

€772.4k

XTRA:PA8

€2.6m

DB:PA8K

€45.7k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

Recent updates

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc., Annual General Meeting, Jun 25, 2024

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Second quarter 2023 earnings released: US$5.18 loss per share (vs US$5.31 loss in 2Q 2022)

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

Now 20% undervalued after recent price drop

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: US$3.22 loss per share (vs US$2.47 loss in 1Q 2022)

Insufficient new directors

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Third quarter 2022 earnings released: US$0.098 loss per share (vs US$0.062 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.098 loss per share (vs US$0.062 loss in 3Q 2021)

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.068 loss in 2Q 2021)

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

First quarter 2022 earnings released: US$0.082 loss per share (vs US$0.07 loss in 1Q 2021)

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

No longer forecast to breakeven

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

VBI Vaccines Inc. Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients

Forecast to breakeven in 2024

VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

VBI Vaccines Announces U.S. Food and Drug Administration Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults

Rendement voor aandeelhouders